Abstract
The 2000s will witness a burgeoning number of biologicals under clinical investigation, either singly or in combination with other biologicals or chemotherapeutic agents. Already, biotherapies have demonstrated efficacy against certain malignancies and are approved for general use in medicine. It is expected that their assimilation into our standard anticancer armamentarium will continue to broaden in the 2000s, leading to the dominance of biotherapy in cancer treatment soon after the year 2004. This chapter will summarize disease-related activity for selected biotherapies as we start the new millennium.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abrams JS, Rayner AA, Wiernik PH. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of of advanced renal cell carcinoma. J Natl Cancer Inst 1990; 82: 1202.
Ahn SS, Irie RF, Weisenburger TH et al. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response. Surgery 1982; 92: 362–7.
Al-Kativ A, Wang CY, Koziner V. Gamma interferon (IFNgamma)-induced phenotypic changes of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) cells. Proc Am Assoc Cancer Res 1984; 25: 235 (abstract).
Alimena G, Morra E, Lazzarino M et al. Interferon alpha-2b as therapy for Ph’-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–7.
Allison MA, Jones SE, McGuffey P. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. J Clin Oncol 1989; 7: 75–80.
Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177–86.
Amato RJ, Murray L, Wood L. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex-96 (HSPP-96) vaccine. Proc Am Soc Clin Oncol 1999; 19: Abstract.
Angevin E, Kremer F, Gaudin C. Analysis of T-cell immune response in renal cell carcinoma: polarization to type I-like differentiation pattern, clonal T-cell expansion, and tumor-specific cytotoxicity. Int J Cancer 1997; 72: 431–40.
Anthony HM, Mearns AJ, Mason MK et al. Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax 1979; 34: 4-
Ardizzoni A, Bonavia M, Viale M et al. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer 1994; 73: 1353–60.
Ardizzoni A, Salvati F, Rosso R et al. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force. Cancer 1993; 72: 2929–2935.
Athanasiadis I, Kies MS, Miller M et al. Phase II study of all-trans-retinoic acid and alpha-interferon in patients with advanced non-small cell lung cancer. Clin Cancer Res 1995; 1: 973–9.
Atkins MB, O’Boyle KR, Sosman JA et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553–60.
Aulitzky W, Gastl G, Aulitzky WE et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989; 7: 1875–84.
Austin FC, Boone CW, Levin DL et al. Breast cancer skin test antigens of increased sensitivity prepared from vesicular stomatitis virus-infected tumor cells. Cancer 1982; 49: 2034–42.
Aviles A, Guzman R, Garcia EL, Diaz-Maqueo JC. Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma. Cancer Biother Radiopharm 1996; 11: 21–4.
Avner BP, Liao SK, Avner B, DeCell K, Oldham RK. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Modif 1989; 8: 25–36.
Ayoub J, Jean-Francois R, Cormier Y et al. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: implications for chemoprevention of lung cancer. J Clin Oncol 1999; 17: 3546–52.
Babaian RJ, Murray JL, Lamki LM et al. Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. J Urol 1987; 137: 439–43.
Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806–11.
Bajorin DF, Chapman PB, Wong G et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50: 7490–5.
Ball ED, Bernier GM, Cornwell GG, III, McIntyre OR, O’Donnell JF, Fanger MW. Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia. Blood 1983; 62: 1203–10.
Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911–14.
Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904–14.
Bedikian AY, Patt YZ, Murphy WK et al. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy. Am J Clin Oncol 1984; 7: 399–404.
Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–7.
Berd D, Maguire HC, Jr., Schuchter LM et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15: 2359–70.
Berek JS, Hacker NF, Knapp R. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Proc Am Soc Clin Oncol 1984; 3: 173 (abstract).
Berek JS, Hacker NF, Lichtenstein A. Intraperitoneal recombinant alpha-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Semin Oncol 1986: 61–71.
Bernstein ZP, Goldrosen MH, Vaickus L et al. Interleukin-2 with ex vivo activated killer cells: therapy of advanced nonsmall-cell lung cancer. J Immunother 1991; 10: 383–7.
Bernstein ZP, Vaickus L, Friedman N et al. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin’s lymphoma and Hodgkin’s disease. J Immunother 1991; 10: 141–6.
Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Br J Cancer 1995; 72: 1551–5.
Bitran JD, Green M, Perry M, Hollis DR, Herndon JE. A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. Am J Clin Oncol 1995; 18: 67–70.
Bjornsson S, Takita H, Kuberka N et al. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guerin or Corynebacterium parvum in stage III lung cancer. Cancer Treat Rep 1978; 62: 505–10.
Blair S, Flaherty L, Valdivieso M. Comparison of high dose interleukin 2 with combined chemotherapy and low dose IL2 in metastatic malignant melanoma. Proc Am Soc Clin Oncol 2003; 3: 294 (abstract).
Bonnem EM, Oldham RK. Gamma-interferon: physiology and speculation on its role in medicine. J Biol Response Modif 1987; 6: 275–301.
Bonnem EM, Spiegel RJ. Interferon-alpha: current status and future promise. J Biol Response Modif 1984; 3: 580–98.
Borden EC. Introduction. In: Borden EC, ed. Melanoma: Biologically Targeted Therapeutics. Totowa: Humana Press, 2002: v-x.
Borden EC, Holland JF, Dao TL et al. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med 1982; 97: 1–6.
Borgstrom S, von Eyben FE, Flodgren P, Axelsson B, Sjogren HO. Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med 1982; 307: 1080–1.
Bouroncle BS, Wiseman BK, Doak CA. Leukemic reticuloendetheliosis. Blood 1958; 13: 609–29.
Brossart P, Stuhler G, Flad T. HER-2/neu derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma cell lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732–6.
Brown SL, Miller RA, Horning SJ et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651–61.
Brown TD, Koeller J, Beougher K et al. A phase I clinical trial of recombinant DNA gamma interferon. J Clin Oncol 1987; 5: 790–8.
Budd GT, Osgood B, Barna B et al. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects. Cancer Res 1989; 49: 6432–6.
Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80: 1198–220.
Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19: 148–54.
Bunn PA, Jr., Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57: 1689–95.
Buzaid AC, Blumenschein GR, Hortovagyi GN. Adjuvant chemotherapy with 4-fluorouracil doxorubicin (Adriamycin) and cyclophosphamide, with or without BCG immunotherapy in state II or stage III breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier North Holland, 1982: 175–81.
Cameron DA, Cornbleet MC, Mackie RM et al. Adjuvant interferon alpha 2b in high risk melanoma–the Scottish study. Br J Cancer 2001; 84: 1146–9.
Cannon B, McCoy JL, Connor RJ et al. Use of the leukocyte migration inhibition assay to evaluate antigenic differences in human breast cancers and melanomas. J Natl Cancer Inst 1978; 60: 969–78.
Carrasquillo JA, Abrams PG, Schroff RW et al. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med 1988; 29: 39–47.
Carrasquillo JA, Bunn PA Jr, Keenan AM et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med 1986; 315: 673–80.
Case DC, Jr, Sonneborn HL, Paul SD et al. Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986; 70: 1251–4.
Castiglione F, Porcile G, Gridelli C. The potential role of amifostine in the treatment of non small cell lung cancer. Lung Cancer 2000; 29: 57–66.
Ceriani RL, Sasaki M, Sussman H, Wara WM, Blank EW. Circulating human mammary epithelial antigens in breast cancer. Proc Natl Acad Sci USA 1982; 79: 5420–4.
Ceriani RL, Thompson K, Peterson JA, Abraham S. Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci USA 1977; 74: 582–6.
Chahinian AP, Goldberg J, Holland JF, Reisman A, Jaffrey IS, Mandel EM. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer. Cancer Treat Rep 1982; 66: 1291–7.
Chapman PB, Kolitz JE, Hakes TB et al. A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs 1988; 6: 179–88.
Cheng AL, Su IJ, Chen CC et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol 1994; 12: 1185–92.
Cheung NK, Lazarus H, Miraldi FD et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430–40.
Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–8.
Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8: 2–11.
Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044–9.
Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958–70.
Clamon G, Herndon J, Perry MC et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 1993; 85: 316–20.
Clark RH, Dimitrov NV, Axelson JA, Charmella LJ. Leukocyte interferon as a biological response modifier in lymphoproliferative diseases resistant to standard therapy. Blood 1983; 62: 188a (abstract).
Clarkson BD, Dowling MD, Gee TS, Cunningham IB, Burchenal JH. Treatment of acute leukemia in adults. Cancer 1975; 36: 775–95.
Coates A, Rallings M, Hersey P, Swanson C. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 1986; 6: 1–4.
Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–48.
Cohen MH, Chretien PB, Ihde DC et al. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. J Am Med Assoc 1979; 241: 1813–15.
Coiffier B, Haioun C, Ketterer N et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32.
Coiffier B, Lepage E, Herbrecht R. Mabthera (Rituxan) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 2000; 96: 223a (abstract).
Coit D, Houghton A, Corden-Cardo C. Isolation limb perfusion with monoclonal antibody R24 in patients with malignant lymphoma. Proc Am Soc Clin Oncol 1988; 7: 248 (abstract).
Colcher D, Esteban J, Carrasquillo JA et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987; 47: 4218–24.
Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199–203.
Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res 1983; 43: 736–42.
Colombat P, Salles G, Brousse N et al. Rituximab (antiCD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–6.
Cooper MR. Interferons in the treatment of multiple myeloma. Semin Oncol 1986; 13: 13–20.
Creagan ET, Ahmann DL, Green SJ et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984; 2: 1002–5.
Creagan ET, Ahmann DL, Green SJ et al. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 1984; 54: 2844–9.
Creagan ET, Dalton RJ, Ahmann DL et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2776–83.
Creekmore S, Urba W, Koop W. Phase IB/II trial of R24 antibody and interleukin-2 (IL2) in melanoma. Proc Am Soc Clin Oncol 1992; 1886: 345 (abstract).
Culver KW, Blaese RM. Gene therapy for cancer. Trends Genet 1994; 10: 174–8.
Czuczman M, Fallow A, Scarpace A. Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma. Blood 2000; 96: 729a (abstract).
Dantal J, Hourmant M, Cantarovich D et al. Effect of longterm immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623–8.
Das D, Ata UR. A novel method for eliminating the melanin pigments from melanoma cells undergoing cytogenetic analysis in cases of uveal melanoma. Cancer Genet Cytogenet 2001; 127: 181–3.
Davis S, Mietlowski W, Rohwedder JJ, Griffin JP, Neshat AA. Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study. Cancer 1982; 50: 646–51.
Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab antiCD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–43.
Davis TA, Maloney DG, Grillo-Lopez AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000; 6: 2644–52.
Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–7.
Day CL, Jr, Lew RA, Mihm MC Jr. et al. A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg 1982; 195: 44–9.
Demchak PA, Mier JW, Robert NJ, O’Brien K, Gould JA, Atkins MB. Interleukin-2 and high dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9: 1821–30.
Devore RF, Fehrenbacher L, Herbst RS. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to VEGF) plus carboplatin.paclitaxel (CP) to CP alone in patient with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19: Abstract.
Diaz RE, Jimeno J, Camps C et al. Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. Cancer Invest 1992; 10: 259–64.
Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989; 111: 592–603.
Dillman RO, Beauregard J, Royston I, Zavanelli MI. Phase II trial of thymosin fraction 5 and thymosin alpha 1. J Biol Response Modif 1987; 6: 263–7.
Dillman RO, Beauregard J, Shawler DL et al. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Response Modif 1986; 5: 394–410.
Dillman RO, Beauregard JC, Shawler DL. In: Peters H, ed. Protides of the Biological Fluids. New York: Pergamon Press, 1983: 353–8.
Dillman RO, Church C, Oldham RK, West WH, Schwartz-berg L, Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993; 71: 2358–70.
Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210–15.
Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, West WH. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 1990; 82: 1345–9.
Dillman RO, Oldham RK, Barth NM et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 1991; 68: 1–8.
Dillman RO, Oldham RK, Tauer KW et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 1991; 9: 1233–40.
Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940–5.
Dillman RO, Shawler DL, Sobol RE et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036–45.
Dimitrov NV, Myer C, Einhorn S. Interferon as modifiers of estrogen receptors in cancer tissues. Proc Am Soc Clin Oncol 1982; 23: 240 (abstract).
DiPaola RS, Rodrigues R, Recio A, Goodin S. A phase I study of amifostine and paclitaxel in patients with advanced malignancies. Proc Am Soc Clin Oncol 1996; 15: 1556a (abstract).
Dorval T, Palangie T, Jouve M et al. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer 1986; 58: 215–18.
Dreno B, Claudy A, Meynadier J et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991; 125: 456–9.
Dreno B, Mansat E, Legoux B, Litoux P. Skin cancers in transplant patients. Nephrol Dial Transplant 1998; 13: 1374–9.
Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–4.
Duggan DB, Santarelli MT, Zamkoff K et al. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin’s lymphoma. A study of the Cancer and Leukemia Group B. J Immunother 1992; 12: 115–22.
Dutcher JP, Atkins M, Fisher R et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989–1997. Cancer J Sci Am 1997; 3 (Suppl. 1): S73–8.
Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581–93.
Edwards FR. Use of BCG as an immunostimulant after resection of carcinoma of the lung: a two-year assessment of a trial of 500 patients. Thorax 1979; 34: 801–6.
Elias DJ, Hirschowitz L, Kline LE et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1 /4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 1990; 50: 4154–9.
Ellerhorst J, Jones E, Kilbourn R. Fixed low dose gamma interferon is active against metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1992; 11: 220 (abstract).
Elsasser-Beile U, Drews H. [Interferon in the treatment of malignant melanoma. Results of clinical studies]. Fortschr Med 1987; 105: 401–3.
Epenetos AA, Munro AJ, Stewart S et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 1890–9.
Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–75.
Escudier B, Chevreau C, Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol 1999; 17: 2039–43.
Esteban JM, Colcher D, Sugarbaker P et al. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987; 39: 50–9.
Ettinger DS, Order SE, Wharam MD, Parker MK, Klein JL, Leichner PK. Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. Cancer Treat Rep 1982; 66: 289–97.
Evans TL, Lynch TJ Jr. Lung cancer. Oncologist 2001; 6: 407–14.
Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403–8.
Fer MF, Beman J, Stevenson HC et al. A trial of autologous plasma perfusion over protein A in patients with breast cancer. J Biol Response Modif 1984; 3: 352–8.
Fer MF, Oldham RK. An immunoadsorption/immunoactivation: a critical review. In: Immune Complexes and Human Cancer. New York: Plenum, 1985: 257–76.
Ferradini L, Mackensen A, Genevee C et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 1993; 91: 1183–90.
Ferraresi R. Enhanced response to chemotherapy after treatment with DNA alpha-2 interferon. Am Soc Hematol 1983; 62: 212a.
Fiedler W, Jasmin C, De Mulder PH et al. A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer 1992; 28: 443–6.
Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161: 381–7.
Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17: 2521–9.
Fintor L. Melanoma vaccine momentum spurs interest, investment. J Natl Cancer Inst 2000; 92: 1205–7.
Fisher RI, Dana BW, LeBlanc M et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18: 2010–16.
Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl. 1): S55–7.
Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3 (Suppl. 1): S70–2.
Flaherty LE, Redman BG, Chabot GG et al. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990; 65: 2471–7.
Flanigan RC, Blumenstein BA, Salmon S. Cytoreductive tumor nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949. J Urol 2000; 163 (Suppl.): 685 (abstract).
Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–9.
Foon K, Doroshow J, Bonnem E et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Modif 1988; 7: 540–5.
Foon KA, Bottino GC, Abrams PG et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78: 216–20.
Foon KA, Maluish AE, Abrams PG et al. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. Am J Med 1986; 80: 351–6.
Foon KA, Schroff RW, Bunn PA et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085–93.
Foon KA, Smalley RV, Riggs CW, Gale RP. The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 1983; 143: 1726–31.
Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317–24.
Foss FM, Raubitscheck A, Mulshine JL et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998; 4: 2691–700.
Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27: 187–193.
Freedman RS, Gutterman JU, Wharton JT, Rutledge FN. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Response Modif 1983; 2: 133–8.
Fujisawa T, Waldman SR, Yonemoto RH. Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients. Cancer 1977; 39: 506–13.
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688–96.
Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14: 2410–11.
Gahery-Segard H, Molinier-Frenkel V, Le Boulaire C et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 1997; 100: 2218–26.
Garaci E, Lopez M, Bonsignore G et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 1995; 31A: 2403–5.
Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081–5.
Gitlitz BJ, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol 2001; 19: 141–7.
Gitlitz BJ, Hoffman DM, Moldawer N, Belldegrun A, Figlin RA. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J 2001; 7: 112–20.
Gleave ME, Elhilali M, Fradet Y. Inteferon gamma-1b compared to placebo in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1265.
Gockerman J, Gregory S, Harwood S. Interim efficacy results of Bexxar in a large multicenter expanded access study. Proc Am Soc Clin Oncol 2001; 20: 285a (abstract).
Goldberg RM, Ayoob M, Silgals R, Ahlgren JD, Neefe JR. Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma. Cancer Treat Rep 1985; 69: 813–16.
Goldenberg D, DeLand FH. History and status of tumor imaging with radiolabeled antibodies. J Biol Response Modif 1982; 1: 121–36.
Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993; 94: 297–312.
Golomb HM. The treatment of hairy cell leukemia. Blood 1987; 69: 979–83.
Golomb HM, Ratain MJ, Fefer A et al. Randomized study of the duration of treatment with interferon alpha-2b in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80: 359–73.
Goncalves A, Camerlo J, Bun H et al. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res 2001; 21: 1431–7.
Goodman GE, Beaumier P, Hellstrom I, Fernyhough B, Hellstrom KE. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3: 340–52.
Goodman GE, Hellstrom I, Brodzinsky L. Phase I trial of monoclonal antibody MG-21 directed against a melanoma-associated GD3 ganglioside antigen. Proc Am Soc Clin Oncol 1987; 6: 209 (abstract).
Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999; 5: 1319–23.
Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36.
Grem JL, Jordan E, Robson ME et al. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993; 11: 1737–45.
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41.
Groopman JE. Therapeutic options in hairy-cell leukemia. Semin Oncol 1985; 12: 30–4.
Gundersen S, Flokkmann A. Interferon plus dacarbazine in advanced malignant melanoma: a phase I- II study. Eur J Cancer 1991; 27: 220–21.
Gutterman JU, Blumenschein GR, Alexanian R et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980; 93: 399–406.
Hagenbeek A, Carde P, Meerwaldt JH et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16: 41–7.
Hainsworth JD, Burris HA, III, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052–6.
Hakes TB, Currie VE, Kaufman RG. CMF +/- levamisole breast adjuvant chemotherapy. Proc Am Soc Clin Oncol 1995; 14: 386 (abstract).
Halpern SE, Dillman RO. Radioimmunodetection with monoclonal antibodies against prostatic acid phosphatase. In: Nuclear Medicine in Clinical Oncology. Berlin: Springer Verlag, 1986: 164–70.
Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145–9.
Herbst RS, Khuri FR, Fossella FV. ZD1839 (Iressa) in non-small lung cancer. Clin Lung Cancer 2001; 3: 27–32.
Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999; 22: 145–54.
Herskovic A, Bauer M, Seydel HG et al. Post-operative thoracic irradiation with or without levamisole in non-small cell lung cancer: results of a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 1988; 14: 37–42.
Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267–79.
Hill NO, Pardue A, Khan A et al. Interferon and cimetidine for malignant melanoma. N Engl J Med 1983; 308: 286.
Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology, and end results program data. J Urol 2002; 167: 57–60.
Hoffman DM, Figlin RA. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000; 18: 152–6.
Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol 2000; 27: 221–33.
Holohan TV, Phillips TM, Bowles C, Deisseroth A. Regression of canine mammary carcinoma after immunoadsorption therapy. Cancer Res 1982; 42: 3663–8.
Holtl L, Rieser C, Papesh C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161: 777–82.
Hoover HC, Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236–43.
Horning SJ, Lucas JB, Younes A. Iodine-131 tositumomab for non-Hodgkin’s lymphoma patients who progressed after treatment with rituximab: results of a multicenter phase II study. Blood 2000; 96: 508a (abstract).
Howard O, Gribben J, Neuberg D. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. Blood 2000; 96: 63 1 a (abstract).
Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 1997; 89: 3129–35.
Issell BF, Valdivieso M, Hersh EM, Richman S, Gutterman JU, Bodey GP. Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep 1978; 62: 1059–63.
Jackson DV, Jr, Paschal BR, Ferree C et al. Combination chemotherapy-radiotherapy with and without the methanol-extraction residue of Bacillus Calmette-Guerin (MER) in small cell carcinoma of the lung: a prospective randomized trial of the Piedmont Oncology Association. Cancer 1982; 50: 48–52.
Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 1992; 12: 70–3.
Jett JR, Maksymiuk AW, Su JQ et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994; 12: 2321–6.
John WJ, Neefe JR, Macdonald JS, Cantrell J Jr, Smith M. 5-Fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules. Cancer 1993; 72: 3191–5.
Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–66.
Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131- anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974–81.
Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (antiCD20) antibody. N Engl J Med 1993; 329: 459–65.
Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001; 19: 3918–28.
Kammula US, White DE, Rosenberg SA. Trends in the safety of highdose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83: 797–805.
Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691–703.
Kataja V, Yap A. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study. Eur J Cancer 1995; 31A: 35–40.
Kavanagh JJ, Kudelka AP, Freedman R. The amelioration of toxicity of intraperitoneal monoclonal Ab 90y-B72.3 with EDTA: a phase I study in refractory ovarian cancer. Proc Am Assoc Cancer Res 1993; 34: 223 (abstract).
Kelley MJ, Linnoila RI, Avis IL et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997; 112: 256–61.
Kelley VE, Fiers W, Strom TB. Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol 1984; 132: 240–5.
Kelly K, Crowley JJ, Bunn PA Jr et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 2924–30.
Kemeny N, Younces A. Alfa-2a interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience. Semin Oncol 1992; 19 (Suppl. 3): 171–5.
Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987; 123: 201–4.
Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173–80.
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin’s lymphoma. Leuk Lymphoma 2001; 41: 77–87.
Khuri FR, Fossella FV, Lee JS et al. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res 1998; 18: 241–5.
Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 1995; 13: 31–44.
Kimura H, Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer. Lung Cancer 1996; 14: 301–14.
Kirkwood JM, Ernstoff M. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol 1986; 13: 48–56.
Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985; 45: 863–71.
Kirkwood JM, Ibrahim JG, Sondak VK et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111 /C9190. J Clin Oncol2000; 18: 2444–58.
Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370–80.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17.
Klefstrom T, Holsti LR, Grohn P, Heinonen E. Combination of levamisole immunotherapy with conventional treatments in breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier, 1982: 187–94.
Kliem V, Kolditz M, Behrend M. Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 1997; 11: 255–8.
Knox S, Hoppe RT, Maloney D et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893–9.
Kowalczyk D, Skorupski W, Kwias Z. Flow cytometric analysis of tumor-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997; 80: 543–7.
Krauss S, Comas F, Perez C et al. Treatment of inoperable non-small cell carcinoma of the lung with radiation therapy, with or without levamisole. A randomized trial of the Southeastern Cancer Study group. Am J Clin Oncol 1984; 7: 405–12.
Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995; 45: 758–62.
Krolick KA, Yuan D, Vitetta ES. Specific killing of a human breast carcinoma cellline by a monoclonal antibody coupled to the A-chain of ricin. Cancer Immunol Immunother 1981; 12: 39–41.
Krown SE. The role of interferon in the therapy of epidemic Kaposi’s sarcoma. Semin Oncol 1987; 14: 27–33.
Krown SE, Pinsky CM, Wanebo HJ, Braun DW Jr, Wong PP, Oettgen HF. Immunologic reactivity and prognosis in breast cancer. Cancer 1980; 46: 1746–52.
Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332–6.
Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209–15.
Lacour J, Lacour F, Spira A et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Br Med J (Clin Res Ed) 1984; 288: 589–92.
Lakhani SR, Ashworth A. Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 2001; 1: 151–7.
Larson SM, Carrasquillo JA, Krohn KA et al. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 1983; 72: 2101–14.
Laszlo J, Hood L, Cox E, Goodwin B. A randomized trial of low doses of alpha interferon in patients with breast cancer. J Biol Response Modif 1986; 5: 206–10.
Lee JS, Lippman SM, Benner SE et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12: 937–45.
Lee KH, Talpaz M, Rothberg JM et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. J Clin Oncol 1989; 7: 1726–32.
Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 2000; 10: 81–92.
Lee YC, Luh SP, Wu RM, Lee CJ. Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection. Cancer Immunol Immun-other 1994; 39: 269–74.
Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16: 34–44.
Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997; 24: S24–31.
Legha SS, Papadopoulos NE, Plager C et al. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 1987; 5: 1240–6.
Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3 (Suppl. 1): S9–15.
LeMaistre CF, Saleh MN, Kuzel TM et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399–405.
Lemkin S, Tokita K, Sherman G. A Phase I-II study of monoclonal antibodies (MCA) in gastrointestinal cancer. Proc Am Soc Clin Oncol 1984; 3: 47 (abstract).
Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 2002; 137: 458–61.
Lentz MR. Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Modif 1989; 8: 511–27.
Lewko WM, Good RW, Bowman D, Smith TL, Oldham RK. Growth of tumor derived activated T-cells for the treatment of cancer. Cancer Biother 1994; 9: 211–24.
Lewko WM, Hall PB, Oldham RK. Growth of tumor-derived activated T cells for the treatment of advanced cancer. Cancer Biother Radiopharm 2000; 15: 357–66.
Lewko WM, Smith TL, Bowman DJ, Good RW, Oldham RK. Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother 1995; 10: 13–20.
Lichtenstein A, Spina C, Berek JS, Jung T, Zighelboim J. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res 1988; 48: 5853–9.
Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep 2002; 4: 510–4.
Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000; 1: 48–56.
Lippman SM, Lee JJ, Karp DD et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93: 605–18.
Lipton A, Harvey HA, Simmonds MA. Lack of enhanced activity of systemic interferon by cimetidine in malignant melanoma. Proc Am Soc Clin Oncol 1984; 3: 56 (abstract).
Lissoni P, Meregalli S, Fossati V et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994; 80: 464–7.
Lissoni P, Tisi E, Barni S et al. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer 1992; 66: 155–8.
Livingston PO, Ritter G, Srivastava P et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49: 7045–50.
LoBuglio AF, Wheeler R, Leavitt RD. Pharmacokinetics and immune response to chimeric mouse/human monoclonal antibody (CH17–1A in man. Proc Am Soc Clin Oncol 1988; 7: 111 (abstract).
Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ. Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 1991; 83: 285–8.
Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus 1984; 6: 27–42.
Lowe J, Iles PB, Shore DF, Langman MJ, Baldwin RW. Intrapleural BCG in operable lung cancer. Lancet 1980; 1: 11–14.
Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1 H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol 1998; 16: 3257–63.
Lynch TJ, Jr, Lambert JM, Coral F et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901- blocked ricin. J Clin Oncol 1997; 15: 723–34.
Maasilta P, Holsti LR, Halme M, Kivisaari L, Cantell K, Mattson K. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 23: 863–8.
Macchiarini P, Hardin M, Angeletti CA. Long-term evaluation of intrapleural Bacillus Calmette-Guerin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 291–7.
Mackenson A, Cercelain G, Viels S. Direct evidence to support the immunosurveillance concept in a regressive melanoma. J Clin Invest 1994; 93: 1402.
Maleckar JR, Friddell CS, Lewko WM, Yannelli JR, West WH, Oldham RK. Tumor-derived activated cells: culture conditions and characterization. Immunol Ser 1989; 48: 159–73.
Maleckar JR, Friddell CS, Sferruzza A et al. Activation and expansion of tumor-derived activated cells for therapeutic use. J Natl Cancer Inst 1989; 81: 1655–60.
Mandanas R, Einhorn LH, Wheeler B, Ansari R, Lutz T, Miller ME. Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer. A Hoosier Oncology Group phase II trial. Am J Clin Oncol 1993; 16: 519–21.
Mandell F, Tribalto M. Recombinant alpha-2b interferon as maintenance therapy in responding multiple myeloma patients. Blood 1987; 70: 247a.
Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27: 194–203.
Margolin KA, Aronson FR, Sznol M et al. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin’s disease and non-Hodgkin’s lymphoma. J Immunother 1991; 10: 214–20.
Martin A, Nerenstone S, Urba WJ et al. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study. J Clin Oncol 1990; 8: 721–30.
Mathe G, Amiel JL, Schwarzenberg L et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1969; 1: 697–9.
Matthay RA, Mahler DA, Beck GJ et al. Intratumoral Bacillus Calmette-Guerin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res 1986; 46: 5963–8.
Mattson K, Niiranen A, Ruotsalainen T et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. J Interferon Cytokine Res 1997; 17: 103–5.
McCracken JD, Chen T, White J et al. Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung: a Southwest Oncology Group Study. Cancer 1982; 49: 2252–8.
McCulloch PB, Poon M, Dent PB, Dawson P. A stratified randomized trial of 5-flurouracil, doxorubicin (Adriamycin) and cyclophosphamide alone or with BCG in stage IV breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier, 1982: 183–6.
McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 1981; 47: 1984–7.
McDermott D, Flaherty L, Clark J et al. A randomized phase III trial of high-dose interleukin-2 (HD IL-2) versus subcutaneous (SC) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2001; 21: Abstract.
McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet 1976; 1: 377–9.
McKneally MF, Maver C, Kausel HW, Alley RD. Regional immunotherapy with intrapleural BCG for lung cancer. J Thorac Cardiovasc Surg 1976; 72: 333–8.
McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 2000; 27: 115–23.
McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33.
Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14–17.
Mellstedt H, Frodin JE, Masucci G. Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma. Oncology (Huntingt) 1989; 3: 25–32.
Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfabased immunotherapy compared with interferon alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966–70.
Millar JW, Roscoe P, Pearce SJ, Ludgate S, Horne NW. Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax 1982; 37: 57–60.
Miller RA, Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 1981; 2: 226–30.
Miller RA, Maloney DG, McKillop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981; 58: 78–86.
Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517–22.
Miller WH Jr. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998; 83: 1471–82.
Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989; 7: 865–8.
Molin L, Thomsen K, Volden G et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987; 67: 232–6.
Moormeier JA, Ratain MJ, Westbrook CA, Vardiman JW, Daly KM, Golomb HM. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst 1989; 81: 1172–4.
Morales A, Ersil A. Adjuvant BCG immunotherapy in the prophylaxis and treatment of non-invasive bladder cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier, 1982: 301–7.
Morton DL. Active immunotherapy against cancer: present status. Semin Oncol 1986; 13: 180–5.
Motzer RJ, Mazumdar M, Bacik J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530–40.
Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928–35.
Motzer RJ, Rakhit A, Ginsberg M et al. Phase I trial of 40- kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312–19.
Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408–17.
Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987; 14: 36–42.
Nabel GJ, Nabel EG, Yang ZY et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307–11.
Namba M, Miyoshi T, Kanamori T. Combined effects of 5- fluorouracil and interferon on proliferation of human neo-plastic cells in culture. Jpn J Cancer Res 1982; 73: 819–24.
National Cancer Institute Lung Cancer Study Group. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg 1981; 82: 649–57.
Neefe JR, Silgals R, Ayoob M, Schein PS. Minimal activity of recombinant clone A interferon in metastatic colon cancer. J Biol Response Modif 1984; 3: 366–70.
Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338: 1272–8.
Neidhart JA, Murphy SG, Hennick LA, Wise HA. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 1980; 46: 1128–34.
Neri N, Aviles A, Cleto S et al. Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. J Hematother Stem Cell Res 2001; 10: 669–74.
Neumann E, Engelsberg A, Decker J. Heterogenous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell based immunotherapies ? Cancer Res 1998; 58: 4090–5.
Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76–82.
Niederle N, Doberauer CK, Kloke O. Treatment of chronic myelogenous leukemia with recombinant interferon-alpha (IFN-2b). Proc Am Soc Clin Oncol 1986; 5: 236 (abstract).
Nio Y, Nagami H, Tamura K et al. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 1999; 80: 775–85.
Norton L, Slamon D, Leyland-Jones B. Overall survival advantage to simultaneous chemotherapy plus humanized anti-HER-2 monoclonal antibody Herceptin in HER-2 over-expressing metastatic breast cancer. Cancer 1998; 83: 1142–50.
O’Brien ME, Saini A, Smith IE et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable nonsmall-cell lung cancer and mesothelioma. Br J Cancer 2000; 83: 853–7.
Oberg K, Norheim I, Lind E et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: longterm results. Cancer Treat Rep 1986; 70: 1297–304.
Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alfa-2a. Cancer 1986; 57: 1685–8.
Oldham RK. Biologicals for cancer treatment: interferons. Hosp Pract 1985; 20: 72–91.
Oldham RK. Monoclonal antibody therapy. In: Chiao JW, ed. Biological Response Modifiers and Cancer Research. New York: Marcel Dekker, 1988: 3–16.
Oldham RK. IL-2 activated tumor derived activated cells. In: Hiddleman, ed. Oncologic Dialogue. 1990.
Oldham RK, Bartal A, Yannelli JR. Intra-arterial and intracavitary administration with advanced cancer: feasibility and laboratory results. Proc Am Assoc Cancer Res 1988: Abstract.
Oldham RK. Biologicals and biological response modifiers: design of clinical trials. J Biol Response Modif 1985; 4: 117–28.
Oldham RK. Cancer cures: by the people, for the people, at what cost? Mol Biother 1990; 2: 2–3.
Oldham RK. Custom-tailored drug immunoconjugates in cancer therapy. Mol Biother 1991; 3: 148–62.
Oldham RK. Therapy with interleukin-2 and tumor-derived activated lymphocytes. Immunol Ser 1994; 61: 251–71.
Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 1992; 4: 4–9.
Oldham RK, Dillman RO, Yannelli JR et al. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial. Mol Biother 1991; 3: 68–73.
Oldham RK, Foon KA, Morgan AC et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984; 2: 1235–44.
Oldham RK, Lewis M, Orr DW et al. Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies. Mol Biother 1988; 1: 103–13.
Oldham RK, Lewko WM, Good RW, Sharp E. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC). In Vivo 1994; 8: 653–63.
Oldham RK, Maleckar JR, Friddell CS, Lewko WM, West WH, Yannelli JR. Tumor-derived activated cells: preliminary laboratory and clinical results. Clin Chem 1989; 35: 1576–80.
Oldham R. Symposium on ex vivo plasma immunoabsorption and protein A in cancer therapy. J Biol Response Modif 1984; 3: 229–30.
Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989; 63: 128.
Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–88.
Olsen EA, Rosen ST, Vollmer RT et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 395–407.
Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5.
Order SE, Stillwagon GB, Klein JL et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol 1985; 3: 1573–82.
Orr D, Oldham R, Lewis M et al. Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies. Mol Biother 1989; 1: 229–40.
Paterson AH, Willans DJ, Jerry LM, Hanson J, McPherson TA. Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J 1984; 131: 744–8.
Pazdur R, Moore DR Jr, Bready B. Modulation of fluorouracil with recombinant alfa interferon: M.D. Anderson Clinical Trial. Semin Oncol 1992; 19 (Suppl. 3): 176–9.
Perez CA, Bauer M, Emami BN et al. Thoracic irradiation with or without levamisole (NSC ##177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG. Int J Radiat Oncol Biol Phys 1988; 15: 1337–46.
Peterson B, Petroni G, Oken M. Cyclophosphamide + interferon alpha-2b in follicular low-grade lymphomas: a preliminary report on an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 1993; 12: 1240 (abstract).
Phillips JL, Pavlovich CP, Walther M, Ried T, Linehan WM. The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. Curr Opin Urol 2001; 11: 463–9.
Pines A. A 5-year controlled study of B.C.G. and radiotherapy inoperable lung cancer. Lancet 1976; 1: 380–1.
Pinsky C, Camcko F, Kerr D. Treatment of superficial bladder cancer with intravesical BCG. Proc Am Soc Clin Oncol 1983; 2: 57 (abstract).
Piro LD, White CA, Grillo-Lopez AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999; 10: 655–61.
Poon MA, O’Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–18.
Prager MD, Baechtel FS, Peters PC. Specific immunotherapy of human metastatic renal cell carcinoma. Proc Am Assoc Cancer Res 1981; 22: 163 (abstract).
Prehn RT. The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Cancer Res 1996; 56: 937–40.
Prior C, Oroszy S, Oberaigner W et al. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J 1997; 10: 392–6.
Puisieux I, Bain C, Merrouche Y. Restriction of the Tcell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma; relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int J Cancer 1996; 66: 201–8.
Punt CJ, Burghouts JT, Croles JJ, van Liessum PA, De Mulder PH, Kamm Y. Continuous infusion of high-dose 5- fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Cancer 1993; 72: 2107–11.
Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10: 1919–26.
Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859–67.
Quan WD Jr, Casal R, Rosenfeld M, Walker PR. Alpha interferon-2b, leucovorin, and 5-fluorouracil (ALF) in non-small cell lung cancer. Cancer Biother Radiopharm 1996; 11: 229–34.
Quesada JR, Alexanian R, Hawkins M et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986; 67: 275–8.
Quesada JR, Evans L, Saks SR, Gutterman J. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J Biol Response Modif 1988; 7: 234–9.
Quesada JR, Hersh EM, Manning J et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68: 493–7.
Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Modif 1987; 6: 20–7.
Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15–18.
Ralph P, Harris PE, Punjabi CJ et al. Lymphokine inducing ‘terminal differentiation’ of the human monoblast leukemia line U937: a role for gamma interferon. Blood 1983; 62: 1169–75.
Ratain MJ, Vardiman JW, Golomb HM. The role of interferon in the treatment of hairy cell leukemia. Semin Oncol 1986; 13: 21–8.
Ratto GB, Zino P, Mirabelli S et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996; 78: 244–51.
Ray PK, Raychaudhuri S, Allen P. Mechanism of regression of mammary adenocarcinomas in rats following plasma adsorption over protein A-containing Staphylococcus aureus. Cancer Res 1982; 42: 4970–4.
Recchia F, De Filippis S, Pompili PL et al. Carboplatin, vindesine, 5-fluorouracil-leucovorin and 13-cis retinoic acid in the treatment of advanced non-small cell lung cancer. A phase II study. Clin Ther 1999; 150: 269–74.
Reily RM. Immunoscintigraphy of tumours using 99Tcmlabelled monoclonal antibodies: a review. Nucl Med Commun 1993; 14: 347–59.
Reintgen DS, McCarty KS Jr, Cox E, Seigler HF. Malignant melanoma in the American black. Curr Surg 1983; 40: 215–17.
Retsas S, Priestman TJ, Newton KA, Westbury G. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 1983; 51: 273–6.
Reuter VE, Presti JC. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000; 27: 124–37.
Richards F, Howard V, Shore A et al. Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-smallcell lung cancer: a prospective randomized study for the Piedmont Oncology Association. Cancer 1981; 47: 2827–32.
Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338–43.
Rinaldi DA, Lippman SM, Burris HA III, Chou C, Von Hoff DD, Hong WK. Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. Anticancer Drugs 1993; 4: 33–6.
Rinehart JJ, Malspeis L, Young D, Neidhart JA. Phase I/II trial of human recombinant interferon gamma and renal cell carcinoma. J Biol Response Modif 1986; 5: 300–8.
Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5: 2766–72.
Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol 2001; 165: 1208–9.
Ritz J, Pesando JM, Sallan SE et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 1981; 58: 141–52.
Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982; 59: 1–11.
Robinson E, Bartal A, Cohen Y, Haasz R, Mekori T. Treatment of lung cancer by radiotherapy, chemotherapy, and methanol extraction residue of BCG (MER): clinical and immunological studies. Cancer 1977; 40: 1052–9.
Roeslin N, Lang JM, Morand G, Wihlm JM, Witz JP. Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study. Cancer Immunol Immunother 1982; 13: 174–5.
Rohatiner A, Radford J, Deakin D et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001; 85: 29–35.
Rohatiner AZ, Balkwill FR, Malpas JS, Lister TA. Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML). Cancer Chemother Pharmacol 1983; 11: 56–8.
Rojas AF, Feierstein JN, Mickiewicz E, Glait H, Olivari AJ. Levamisole in advanced human breast cancer. Lancet 1976; 1: 211–15.
Romaguera JE, Dang NH, Hagemeister FB. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma. Blood 2000; 96: 733a (abstract).
Rosen ST, Zimmer AM, Goldman-Leikin R et al. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 1987; 5: 562–73.
Rosenberg SA. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin Oncol 1986; 13: 200–6.
Rosenberg SA. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180–99.
Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–8.
Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.
Rosenberg SA, Lotze MT, Yang JC. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622.
Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–84.
Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863–74.
Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319: 1676–80.
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–21.
Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159–66.
Roth MD, Gitlitz BJ, Kiertscher SM et al. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res 2000; 60: 1934–1.
Rousseau RF, Hirschmann-Jax C, Takahashi S, Brenner MK. Cancer vaccines. Hematol Oncol Clin N Am 2001; 15: 741–73.
Rubin SC. Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer 1993; 71: 1602–12.
Rudczynski AB, Dyer CA, Mortensen RF. Detection of cell-mediated immune reactivity of breast cancer patients by the leukocyte adherence inhibition response to MCF-7 extracts. Cancer Res 1978; 38: 3590–4.
Ruotsalainen T, Halme M, Isokangas OP et al. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer–a feasibility study. Anticancer Drugs 2000; 11: 101–8.
Ruotsalainen TM, Halme M, Tamminen K et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. J Interferon Cytokine Res 1999; 19: 253–9.
Salvati F, Rasi G, Portalone L, Antilli A, Garaci E. Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Res 1996; 16: 1001–4.
Sarna GP, Lowitz BB, Haskell CM, Dorey FJ, Cline MJ. Chemo-immunotherapy for unresectable bronchogenic carcinoma. Cancer Treat Rep 1978; 62: 681–7.
Scher HI, Shank B, Chapman R et al. Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer Res 1988; 48: 1663–70.
Schiller JH, Storer B, Dreicer R, Rosenquist D, Frontiera M, Carbone PP. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J Natl Cancer Inst 1989; 81: 1739–43.
Schlom J, Wunderlich D, Teramoto YA. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci USA 1980; 77: 6841–5.
Schmid-Wendtner MH, Baumert J, Schmidt M et al. Late metastases of cutaneous melanoma: an analysis of 31 patients. J Am Acad Dermatol 2000; 43: 605–9.
Schmidt-Wolf IG, Finke S, Trojaneck B et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81: 1009–16.
Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 21: 736–44.
Schroff RW, Woodhouse CS, Foon KA et al. Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. J Natl Cancer Inst 1985; 74: 299–306.
Scorticatti CH, de la Pena NC, Bellora OG, Mariotto RA, Casabe AR, Comolli R. Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. J Interferon Res 1982; 2: 339–43.
Sears HF, Herlyn D, Steplewski Z, Kropowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 1984; 3: 138–50.
Sears HF, Atkinson B, Mattis J et al. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1: 762–5.
Selvaggi G, Belani CP. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Semin Oncol 1999; 26: 51–60.
Serrou B, Sancho-Garnier H, Cappelaere P. Inefficacy of post radiotherapeutic BCG immunotherapy in T3 -T4 breast cancer patients: a randomized trial. In: Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier, 1982: 195–8.
Sertoli MR, Bernengo MG, Ardizzoni A et al. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 1989; 46: 96–8.
Sertoli MR, Quierolo P, Bajetta E. Dacarbazine (DTIC) with or without recombinant interferon alpha 2a at different dosages in the treatment of stage IV melanoma patient: preliminary results of a randomized trial. Proc Am Soc Clin Oncol 1992; 11: 345 (abstract).
Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2001; 34 (Suppl.): 81–9.
Silva RR, Bascioni R, Rossini S et al. A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer. Tumori 1996; 82: 68–71.
Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537–46.
Smalley RV, Andersen JW, Hawkins MJ et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 1992; 327: 1336–41.
Smalley RV, Bartolucci AA, Moore M et al. Southeastern Cancer Study Group: breast cancer studies 1972–1982. Int J Radiat Oncol Biol Phys 1983; 9: 1867–74.
Smalley RV, Weller E, Hawkins MJ et al. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin’s lymphoma treated with interferon alfa (IFNalpha2a) plus an anthracycline-based induction regimen. Leukemia 2001; 15: 1118–22.
Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med 1993; 329: 1608–14.
Sosman JA, Hank JA, Sondel PM. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. Semin Oncol 1990; 17: 22–30.
Souter RG, Gill PG, Gunning AJ, Morris PJ. Failure of specific active immunotherapy in lung cancer. Br J Cancer 1981; 44: 496–501.
Sparano JA, Fisher RI, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969–77.
Spitler LE, del Rio M, Khentigan A et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 1987; 47: 1717–23.
Srivastava P. Interaction of Heat Shock Proteins with Peptides and Antigen Presenting Cells: Chaperoning of the Innate and Adaptive Immune Responses. Annu Rev Immunol 2002; 20: 395–425.
Srivastava P, Kumar S, Mendonca C. Principles and practice of the use of heat-shock protein-peptide complexes for immunotherapy of human cancer. Princ Pract Biol Ther Cancer Updates 2001; 2: 1–13.
Steele G Jr, Wang BS, Richie JP, Ervin T, Yankee R, Mannick JA. Results of xenogeneic I-RNA therapy in patients with metastatic renal cell carcinoma. Cancer 1981; 47: 1286–8.
Steineck G, Strander H, Carbin BE et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990; 29: 155–62.
Steiner A, Wolf C, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987; 113: 459–65.
Steis RG, Carrasquillo JA, McCabe R et al. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 1990; 8: 476–90.
Stoter G, Aamdal S, Rodenhuis S et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991; 9: 1687–91.
Study Group for Bronchogenic Carcinoma. Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial. Br Med J 1975; 3: 461–4.
Sznol M, Clark JW, Smith JW et al. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 1992; 84: 929–37.
Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–9.
Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280–8.
Tan AR, Swain SM. Novel agents: clinical trial design. Semin Oncol 2001; 28: 148–53.
Tan Y, Xu M, Wang W et al. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 1996; 16: 1993–8.
Tanaka F, Yonemoto RH, Waldman SR. Blocking factors in sera of breast cancer patients. Cancer 1979; 43: 838–47.
Tannehill SP, Mehta MP, Larson M et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol 1997; 15: 2850–7.
Tapper H, Klein H, Rubenstein W, Intriere L, Choi Y, Kazam E. Recurrent renal cell carcinoma after 45 years. Clin Imaging 1997; 21: 273–5.
Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981; 28: 17–21.
Terman DS, Yamamoto T, Mattioli M et al. Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureus Cowans I. I. Description of acute tumoricidal response: morphologic, histologic, immunohistochemical, immunologic, and serologic findings. J Immunol 1980; 124: 795–805.
Terman DS, Young JB, Shearer WT et al. Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. N Engl J Med 1981; 305: 1195–200.
Tester WJ, Kim KM, Krigel RL et al. A randomized phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 1999; 25: 199–206.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–5.
The Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer 1986; 58: 2411–16.
The Ludwig Lung Cancer Study Group. Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. Cancer Immunol Immunother 1986; 23: 1–4.
Thomson DB, Adena M, McLeod GR et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133–8.
Torti FM, Chotliffe LD, Wiliams RD. Superficial bladder cancers are responsive to alpha 2 interferon administered intravesically. Proc Am Soc Clin Oncol 1984; 3: 160 (abstract).
Torti FM, Lum BL. Superficial carcinoma of the bladder: natural history and the role of interferons. Semin Oncol 1986; 13: 57–60.
Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 1998; 38: 669–80.
Tsui K, Shvarts O, Smith RB, Figlin R, deKernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000; 163: 426–30.
Tummarello D, Graziano F, Isidori P et al. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study. Cancer 1996; 77: 2251–7.
Tykka H, Hjelt L, Oravisto KJ, Turunen M, Tallberg T. Disappearance of lung metastases during immunotherapy in five patients suffering from renal carcinoma. Scand J Respir Dis Suppl 1974; 89: 123–34.
Unterhalt M, Herrmann R, Tiemann M et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin’s lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996; 10: 836–43.
Vadhan-Raj S, Cordon-Cardo C, Carswell E et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglio-side in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636–48.
van Zandwijk N, Groen HJ, Postmus PE et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997; 33: 1759–66.
Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992; 148: 1247.
Vokes EE, Figlin R, Hochster H, Lotze M, Rybak ME. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. Cancer J Sci Am 1998; 4: 46–51.
Vokes EE, Haraf DJ, Hoffman PC. Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study. Cancer Chemother Pharmacol 1993; 33: 203–9.
Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001; 19: 389–97.
Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000; 18: 1316–23.
Vose JM, Zelenetz AD, Rohatiner A. Iodine I 131 tositumomab for patients with follicular non-Hodgkin’s lymphoma: overall clinical trial experience by histology. Blood 1999; 94: 89a (abstract).
Vosika GJ. Clinical immunotherapy trials of bacterial components derived from mycobacteria and nocardia. J Biol Response Modif 1983; 2: 321–42.
Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9: 1806–10.
Wadler S, Schwartz EL, Goldman M et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–75.
Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990; 50: 5735–9.
Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17: 16–21.
Waldmann TA, Goldman CK, Bongiovanni KF et al. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti -Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805–16.
Weber J. Peptide vaccines for cancer. Cancer Invest 2002; 20: 208–21.
Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin’s lymphoma. J Clin Oncol 1992; 10: 33–40.
Weese J, Oldham RK, Tormey DC. Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet 1997; 145: 208–18.
Weh HJ, Platz D, Braumann D. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: Preliminary data of a phase II study. Semin Oncol 2003; 19 (Suppl. 3): 180–4.
Weiner LM, Moldofsky PJ, Gatenby RA et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17–1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568–73.
Weiner LM, O’Dwyer J, Kitson J et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 1989; 49: 4062–7.
Weiner LM, Steplewski Z, Koprowski H, Sears HF, Litwin S, Comis RL. Biologic effects of gamma interferon pretreatment followed by monoclonal antibody 17–1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986; 5 (Suppl. 1): S65–77.
Welander C, Homesley H, Levin E, Reich S. Phase II trial of the efficacy of human recombinant interferon gamma (rIFN gamma) in recurrent ovarian adenocarcinomas. Proc Am Soc Clin Oncol 1986; 5: 221 (abstract).
Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638–45.
West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.
Wheatley K, Hancock B, Gore M, Suciu S, Eggermont AMM. Interferon-a as adjuvant therapy for melanoma: a meta-analysis of the randomised trials. Proc Am Soc Clin Oncol 2001; 20: 1394 (abstract).
White JE, Chen T, Reed R et al. Limited squamous cell carcinoma of the lung: a Southwest Oncology Group randomized study of radiation with or without doxorubicin chemotherapy and with or without levamisole immunotherapy. Cancer Treat Rep 1982; 66: 1113–20.
Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am 1993; 20: 283–95.
Wiseman GA, White CA, Witzig TE et al. Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999; 5: 3281s - 6s.
Witzig TE, Gordon LI, Wiseman GA. Reduced dose Zevalin is safe and effective inpatients with relapsed or refractory, low grade, follicular or CD20+ transformed B cell non Hodgkin’s lymphoma and mild thrombocytopenia. Blood 2000; 96: 728a (abstract).
Witzig TE, Gordon LI, Wiseman GA. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory B cell non-Hodgkin’s lymphoma. Blood 2000; 96: 731 a (abstract).
Witzig TE, White CA, Flinn IW. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma. Blood 2000; 96: 507a (abstract).
Witzig TE, White CA, Gordon LI. Final results of a randomized controlled study of Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood 2000; 96: 83 1 a (abstract).
Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17: 3793–803.
Woodruff M, Walbaum P. A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer. Cancer Immunol Immunother 1983; 16: 114–16.
Wright PW, Hill LD, Peterson AV Jr et al. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guerin plus levamisole treatment of resectable lung cancer. Cancer Treat Rep 1978; 62: 1671–5.
Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1997; 3 (Suppl. 1): S79–84.
Yano T, Ichinose Y, Yokoyama H, Fukuyama Y, Sugio K, Sugimachi K. Inhalation therapy using a streptococcal preparation (OK-432) against bronchioloalveolar carcinoma of the lung. Anticancer Res 1999; 19: 5511–14.
Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980; 125: 238–45.
Yuan D, Hendler FJ, Vitetta ES. Characterization of a monoclonal antibody reactive with a subset of human breast tumors. J Natl Cancer Inst 1982; 68: 719–28.
Zarogoulidis K, Ziogas E, Papagiannis A et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer 1996; 15: 197–205.
Zelenetz AD, Vose JM, Knox S. Iodine I 131 tositumomab for patients with transformed low-grade non-Hodgkin’s lymphoma: overall clinical trial experience. Blood 1999; 94: 632a (abstract).
Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649–57.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Ebbinghaus, S., Oldham, R.K., Dillman, R.O. (2003). Cancer biotherapy: 2003 disease-related activity. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-2757-0_20
Download citation
DOI: https://doi.org/10.1007/978-94-017-2757-0_20
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-2759-4
Online ISBN: 978-94-017-2757-0
eBook Packages: Springer Book Archive